Document is current
Any future updates will be listed below
-
Authors
Essink, Sharon C. M. https://orcid.org/0000-0003-2079-4816
Zomerdijk, Inge M. https://orcid.org/0009-0007-7506-1544
Straus, Sabine M. J. M. https://orcid.org/0009-0006-9266-3312
Gardarsdottir, Helga https://orcid.org/0000-0001-5623-9684
De Bruin, Marie L. https://orcid.org/0000-0001-9197-7068
-
Funding
Funding for this research was provided by:
College ter Beoordeling van Geneesmiddelen
- License Information
-
More Information
Article History
Accepted: 31 March 2025
First Online: 10 April 2025
Declarations
:
: This research was funded with a grant from the Dutch Medicines Evaluation Board (MEB), as part of the regulatory science collaboration between the MEB and Utrecht University.
: Sharon C.M. Essink, Inge M. Zomerdijk, Sabine M.J.M. Straus, Helga Gardarsdottir, and Marie L. De Bruin declare that they have no conflicts of interest to declare that are relevant to the content of this article.
: Not applicable as no human subjects/data are involved.
: Not applicable.
: Not applicable.
: The raw data that support the findings of this study are provided in the Supplementary Table . Data is analysed using Microsoft Excel and SPSS version 28.0.1.1, and R version 4.1.2. Codes are available, together with the full Excel data file, from the corresponding author upon request.
: All authors contributed to the study conception and design. Data collection and analysis were performed by Sharon C.M. Essink, Inge M. Zomerdijk, and Marie L. De Bruin, and discussed with Sabine M.J.M. Straus and Helga Gardarsdottir. The first draft of the manuscript was written by Sharon C.M. Essink and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
